Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease

Clin Chim Acta. 2012 Jan 18;413(1-2):113-20. doi: 10.1016/j.cca.2011.09.004. Epub 2011 Sep 22.

Abstract

Background: Mediators involved in atherosclerosis and plaque rupture may have importance as risk markers for coronary artery disease (CAD). We have investigated the influence of matrix metalloproteinase (MMP)-9 genetic variations on gene- and protein expression in stable CAD patients.

Methods: The promoter -1562C/T and exon 6 R279Q A/G polymorphisms were determined in 1001 patients with angiographically verified stable CAD and in 204 healthy controls. Genotype and gene-expression were determined by real-time PCR. Serum levels of MMP-9 and its inhibitor TIMP-1were measured immunologically and by zymography (MMP-9 activity).

Results: None of the polymorphisms associated with the presence of CAD, myocardial infarction or type 2 diabetes, whereas the variant allele of the R279Q polymorphism associated with hypertension (adjusted p=0.015). The T- and G alleles associated with lower and higher mRNA levels, respectively (p<0.005 both), also shown in an experimental ex-vivo LPS stimulated model. T-allele carriers had higher concentrations of MMP-9 (adjusted p=0.032) and the GG genotype induced lower MMP-9 gelatinolytic activity (p=0.01). Higher MMP-9 gene-expression and TIMP-1 levels were observed in patients with previous myocardial infarction, the latter also was elevated in diabetics (<0.05, all).

Conclusion: The investigated MMP-9 polymorphisms influenced gene- and protein expression differently and the R279Q polymorphism associated significantly with hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Base Sequence
  • Case-Control Studies
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / enzymology*
  • DNA Primers
  • Diabetes Mellitus, Type 2 / genetics
  • Female
  • Genetic Variation*
  • Humans
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Matrix Metalloproteinase 9 / genetics
  • Middle Aged
  • Myocardial Infarction / genetics
  • Polymorphism, Genetic
  • Promoter Regions, Genetic
  • RNA, Messenger / genetics
  • Real-Time Polymerase Chain Reaction
  • Tissue Inhibitor of Metalloproteinase-1 / blood

Substances

  • DNA Primers
  • RNA, Messenger
  • Tissue Inhibitor of Metalloproteinase-1
  • Matrix Metalloproteinase 9